MASS - NASDAQ
908 Devices Inc.
$8.66
-2.1%908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry (Mass Spec) devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of gas, liquid, and solid materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. It operates in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.
At a Glance
Live Snapshot908 Devices Inc. Management Team
Mr. Joseph H. Griffith IV
Chief Financial Officer & Treasurer
Compensation
$576,022
Mr. Michael S. Turner Esq., J.D.
Chief Legal & Administrative Officer and Secretary
Compensation
$470,646
Dr. Christopher David Brown Ph.D.
Co-Founder & Board Advisor
Compensation
$555,607
Dr. Kevin J. Knopp Ph.D.
Co-Founder, Chief Executive Officer, President & Director
Compensation
$993,288
Mr. Don Osmer
Vice President of Human Resources
Ms. Barbara Russo
Vice President of Marketing & Corporate Communications
908 Devices Inc. Insider Positioning
During the last 12 months, insiders have purchased $328K and sold $1.58M worth of MASS shares, resulting in $1.25M of net selling activity.
3 Months
0
0.00
124.2K
909.71K
-910K
-$910K
3-6 Months
0
0.00
58.0K
358.16K
-358K
-$358K
6-9 Months
0
0.00
10.0K
80.58K
-81K
-$81K
9-12 Months
52.1K
327.96K
31.5K
233.92K
+94K
+$94K
Top Buyers
Leonhart Michele M.
Director
$47K
George Jeffrey P.
Director
$47K
Hrusovsky E Kevin
Director
$47K
Hunt Anthony
Director
$47K
Eloi Fenel M
Director
$47K
Top Sellers
Brown Christopher D.
Director
$427K
Griffith Joseph H. Iv
Officer: Chief Financial Officer
$273K
Knopp Kevin J.
Director, Officer: President And Ceo
$215K
Kenneweg John
Officer: Svp, Sales & Product Marketing
$201K
Mccallion Kevin J.
Officer: Svp, Products And Production
$188K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $1.25M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Weak buy/sell ratio. Selling significantly exceeds buying—monitor for potential fundamental concerns.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider buyers and 5 sellers. Equal participation suggests mixed or neutral insider views.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
MASS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | June 11, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 28, 2025 | June 12, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 29, 2024 | June 13, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | May 01, 2023 | June 15, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 21, 2022 | June 16, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 29, 2021 | June 17, 2021 | 2021 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.